MindWalk Holdings Corp. filings document a foreign private issuer that furnishes Form 6-K reports for U.S. market disclosure. The company’s regulatory record includes earnings releases, IFRS-tagged financial data, press releases on Bio-Native AI platform developments, and exhibits covering technologies such as LensAI, HYFT, and B Cell Llama.
The filings also disclose capital-structure and governance items, including issued capital, restricted share units, stock options, lease liabilities, product sales, internally generated development costs, and corporate segment data. Separate 6-K submissions provide SEDI insider activity reports, reflecting the company’s foreign private issuer treatment and exemption from Section 16 Form 4 reporting requirements.
MindWalk Holdings Corp. reported strong top-line growth for Q3 fiscal 2026 while remaining loss-making. Revenue reached $4.2 million, up 52% from $2.7 million a year earlier, marking a third consecutive quarter of year-over-year growth. US revenue doubled to $2.6 million, and gross margin for the quarter was 59%, with year-to-date gross margin improving to 58% from 53%.
The company posted a Q3 net loss from continuing operations of $3.9 million, compared with a $22.0 million loss in the prior-year quarter that included a $21.2 million impairment. For the first nine months, revenue rose to $11.4 million from $7.9 million, while the net loss from continuing operations was $11.2 million. Cash and equivalents were $14.2 million as of January 31, 2026, up from $10.8 million at the start of the period, helped by proceeds from the sale of its Europe B.V. business.
Commercially, MindWalk signed its first one-year LensAI™ platform contract with its largest enterprise AI client, creating its first contracted, recurring platform revenue stream. The company also launched its B cell Llama™ nanobody discovery platform and advanced pipeline programs in dengue, GLP-1, and influenza toward further preclinical data.
MindWalk Holdings Corp. introduced B Cell Llama™, a new platform to discover VHH nanobodies, the single‑domain antibody fragments used in bispecific antibodies, multispecific drugs, and CAR‑T cell therapies. The platform extends the company’s existing B Cell Select® technology into llama‑derived antibodies.
A peer‑reviewed study in ACS Biomacromolecules underpins the launch, showing multivalent VHH formats achieved sub‑nanomolar potency, restored activity against resistant variants, and suggested a potential immune‑priming effect. The work also showed that strong binding alone did not guarantee functional activity, supporting MindWalk’s LensAI™ focus on function‑based candidate selection.
The company positions B Cell Llama™ within a broader bio‑native AI strategy that already supports programs in dengue, universal influenza, GLP‑1 and longevity therapeutics, ALK‑1 oncology and rare disease, and other nanobody therapeutics, while holding first rights to commercialize jointly developed intellectual property from the collaboration.
MindWalk Holdings Corp. announced it will report financial results for its third quarter of fiscal year 2026 on March 12, 2026. The company will issue a press release before holding a webcasted earnings conference call at 10:30 AM Eastern Time that includes a management presentation and Q&A.
The live webcast and replay will be accessible through the Events section of MindWalk’s investor relations website. Dial-in numbers are provided for U.S. and Canadian participants, and the company encourages listeners to review its periodic reports and risk factor discussions on SEDAR+ and the SEC’s website.
MindWalk Holdings Corp. filed a Form 6-K highlighting a new application of its proprietary HYFT® technology to detect “functional adjacency” in drug discovery. Functional adjacency means different molecules can deliver the same biological effect even when their sequences look unrelated, which can affect competition, intellectual property, and asset valuation.
Using HYFT in influenza, MindWalk reports finding a conserved biological “signature” that remains stable despite significant genetic changes, supporting its approach to designing broader vaccine targets. The company positions HYFT as part of a broader data and biological reasoning platform intended to help pharmaceutical and biotechnology organizations assess functional competitors, IP exposure, and portfolio risk, and to inform licensing, M&A diligence, and R&D prioritization.
MindWalk Holdings Corp. filed a report highlighting a new scientific discovery that supports its drug discovery platform. The company has identified and validated monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein linked to amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease. The work shows the platform can distinguish toxic protein conformations from healthy ones with structural precision and tie these findings to bio-native wet-lab validation. MindWalk notes that this discovery provides external, client-driven validation of its platform and reinforces its role as a discovery partner for complex neurodegenerative programs. The full study is available as a preprint on bioRxiv under the title “Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43.”
MindWalk Holdings Corp. filed a report highlighting new progress in its universal influenza program. Using its patented HYFT Deep Data technology and LensAI platform, the company reports finding a stable functional constraint in influenza biology that appears to persist beneath changing viral genetic sequences. This HYFT-defined pattern was observed across human influenza A, including H3N2 and H3N2 subclade K, avian H5, H7, H9, swine-origin H1N1, and influenza B Victoria and Yamagata lineages.
MindWalk describes this constraint as an evolutionary requirement the virus must satisfy for infection, positioning it as a potential target for rational vaccine design. The company plans to advance the influenza program through additional pre-clinical validation and IND-enabling work in a dedicated portfolio, then pursue out-licensing or strategic development partnerships with global pharmaceutical companies, while also exploring strategic investments and other financing alternatives related to the program.
MindWalk Holdings Corp. filed a Form 6-K as a foreign private issuer, furnishing updated quarterly information for investors. The filing includes Management’s Discussion and Analysis and Condensed Interim Consolidated Financial Statements for the three and six months ended October 31, 2025 and 2024, giving more detail on the company’s recent operating and financial performance.
The filing also states that Exhibits 99.1 and 99.2 are incorporated by reference into MindWalk’s existing registration statements on Form S-8 and Form F-3, which relate to previously registered securities. In addition, CEO and CFO certifications pursuant to Canadian regulations are provided as Exhibits 99.3 and 99.4, and the report is signed on behalf of the company by Chief Executive Officer Jennifer Bath.
MindWalk Holdings Corp. (HYFT) entered a Sales Agreement enabling an at‑the‑market offering of up to $30 million in common shares. The company may offer and sell shares from time to time through JonesTrading Institutional Services LLC as sales agent, under its effective Form F‑3 shelf, as supplemented by a prospectus dated November 7, 2025.
Shares may be sold on The Nasdaq Capital Market or other existing trading markets using methods permitted by law and deemed an “at the market offering” under Rule 415(a)(4). The company is not obligated to sell any shares. JonesTrading’s compensation is 3.0% of the gross proceeds of any shares sold. The agreement may be terminated by either party as provided in the contract.